Infant Formula HMO Concentration for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for nutritional compositions, such as infant formulas, that can prevent or reduce the development of allergic sensitization in infants, as existing formulas lack effective components to modulate the immune system and address the increasing incidence of allergic diseases like atopic dermatitis and food allergy.
Innovation Solution
Infant formulas containing specific levels of 2′-fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT) are formulated to prevent or reduce allergic sensitization, with optimal intermediate dosages of 0.8-2.5 g/L for 2′FL and 0.05-0.2 g/L for LNnT, which are identified through analysis of breast milk and animal model studies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infant formulas contain high levels of HMOs (2′FL and LNnT), then allergic response reduction is enhanced, but manufacturing cost and formulation complexity increase
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration levels of specific HMOs (2′FL and LNnT) to intermediate ranges (2′FL: 0.8-2.5 g/L, LNnT: 0.05-0.2 g/L) rather than using high levels. This parameter optimization achieves effective allergic response reduction while avoiding the formulation complexity and cost associated with high-concentration HMO formulations.
Solution Approach 2:
The patent implements partial action by selecting intermediate rather than high levels of HMO supplementation. The data shows that intermediate levels of 2′FL and LNnT provide optimal protection against allergic sensitization, achieving sufficient immune modulation without the excessive action that would lead to formulation complexity and increased manufacturing costs.
2Device complexity
If infant formulas contain low levels of HMOs (2′FL and LNnT), then formulation simplicity is maintained, but allergic response modulation is insufficient
Solution Approach 1:
The patent resolves this contradiction through parameter optimization by establishing that intermediate levels of HMOs (2′FL: 0.8-2.5 g/L, LNnT: 0.05-0.2 g/L) provide optimal allergic response modulation. This parameter range maintains relative formulation simplicity while achieving sufficient immune modulation effectiveness, avoiding both the insufficiency of low levels and the complexity of high levels.
Solution Approach 2:
The patent applies partial action by using intermediate rather than low levels of HMOs. The intermediate concentration provides adequate immune modulation to protect against allergic sensitization, overcoming the insufficiency of low levels while maintaining formulation simplicity better than high-level formulations would.
3Reliability
If synthetic HMOs are added to infant formulas, then immune system modulation is improved, but nutritional composition complexity increases
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration parameters of synthetic HMOs (2′FL and LNnT) to intermediate levels. This optimization achieves effective immune system modulation while controlling nutritional composition complexity, as the specific parameter ranges allow for precise formulation without excessive complexity.
Solution Approach 2:
The patent uses synthetic HMOs as intermediary substances to mediate between the infant formula base and the immune system. By selecting intermediate concentration levels of these intermediary HMOs, the patent achieves immune modulation effectiveness while avoiding the complexity that would arise from multiple different additives or high-concentration single additives.
Data Source
AI summary
An infant formula for use in preventing or reducing the occurrence of allergic sensitisation in an infant, wherein the infant formula comprises 0.8-2.5 g/L 2′-fucosyllactose (2′FL) and/or 0.05-0.2 g/L lacto-N-neotetraose (LNnT).